Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors

European Journal of Medicinal Chemistry

Volumn 61, Issue , 2013, Pages 132-145

  Mowafy, Samar ^a   Farag, Nahla A ^a   Abouzid, Khaled A M ^b  

^a Misr International University   (Egypt)

^b Ain Shams University   (Egypt)

Author keywords

4 Anilinoquinazoline; Anti proliferative activity; Docking study; EGFR TK inhibitors

Indexed keywords

4 (4 CHLOROPHENYLAMINO) 6 UREIDOQUINAZOLINE; 4 ANILINO 6 SUBSTITUTED QUINAZOLINE DERIVATIVE; ADENOSINE TRIPHOSPHATE; CYSTEINE; ENAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOLECULAR DOCKING; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874930214     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.10.017     Document Type: Article

References (47)

1. M.A. Olayioye, R.M. Neve, H.A. Lane, and N.E. Hynes The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J. 19 2000 3159 3167
2. W. Alan EGF receptor Int. J. Biochem. Cell. Biol. 31 1999 637 643
3. H.-Q. Li, D.-D. Li, X. Lu, Y.-Y. Xu, and H.-L. Zhu Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity Bioorg. Med. Chem. 20 2012 317 323
4. W.J. Gullick Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers Br. Med. Bull. 47 1991 87 98
5. C.J. Wikstrand, R.E. McLendon, A.H. Friedman, and D.D. Bigner Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII Cancer Res. 57 1997 4130 4140
6. W.K. Hong, and A. Ullrich The role of EGFR in solid tumors and implications for therapy Oncol. Biother. 1 2000 1 29
7. E. Zwick, J. Bange, and A. Ullrich Receptor tyrosine kinase signalling as a target for cancer intervention strategies Endocr. Relat. Cancer 8 2001 161 173
8. C. Fernandes, C. Oliveira, L. Gano, A. Bourkoula, I. Pirmettis, and I. Santos Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer Bioorg. Med. Chem. 15 2007 3974 3980
9. L.T. Liu, T.-T. Yuan, H.-H. Liu, S.-F. Chen, and Y.-T. Wu Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors Bioorg. Med. Chem. Lett. 17 2007 6373 6377
10. J.C. Delarue, P. Terrier, M.J. Terrier-Lacombe, H. Mouriesse, M. Gotteland, and F. May-Levin Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study Bull. Cancer 81 1994 1067 1077
11. S.M. Abou-Seri Synthesis and biological evaluation of novel 2,4′-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors Eur. J. Med. Chem. 45 2010 4113 4121
12. A. Antonello, A. Tarozzi, F. Morroni, A. Cavalli, M. Rosini, P. Hrelia, M.L. Bolognesi, and C. Melchiorre Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects† J. Med. Chem. 49 2006 6642 6645
13. B.C. Roger Epidermal growth factor receptor as a therapeutic target in colorectal cancer Clin. Colorectal Cancer 2 2003 246 251
14. J.J.-L. Liao Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 50 2007 409 424
15. J. Stamos, M.X. Sliwkowski, and C. Eigenbrot Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 277 2002 46265 46272
16. R.-D. Li, X. Zhang, Q.-Y. Li, Z.-M. Ge, and R.-T. Li Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines Bioorg. Med. Chem. Lett. 21 2011 3637 3640
17. P. Ballard, R.H. Bradbury, C.S. Harris, L.F.A. Hennequin, M. Hickinson, P.D. Johnson, J.G. Kettle, T. Klinowska, A.G. Leach, R. Morgentin, M. Pass, D.J. Ogilvie, A. Olivier, N. Warin, and E.J. Williams Inhibitors of epidermal growth factor receptor tyrosine kinase: novel C-5 substituted anilinoquinazolines designed to target the ribose pocket Bioorg. Med. Chem. Lett. 16 2006 1633 1637
18. V.G. Pawar, M.L. Sos, H.B. Rode, M. Rabiller, S. Heynck, W.A.L. van Otterlo, R.K. Thomas, and D. Rauh Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor J. Med. Chem. 53 2010 2892 2901
19. J.B. Smaill, G.W. Rewcastle, J.A. Loo, K.D. Greis, O.H. Chan, E.L. Reyner, E. Lipka, H.D.H. Showalter, P.W. Vincent, W.L. Elliott, and W.A. Denny Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d] pyrimidine-6-acrylamides bearing additional solubilizing functions J. Med. Chem. 43 2000 1380 1397
20. W.A. Denny Irreversible inhibitors of the erbB family of protein tyrosine kinases Pharmacol. Ther. 93 2002 253 261
21. J.B. Smaill, B.D. Palmer, G.W. Rewcastle, W.A. Denny, D.J. McNamara, E.M. Dobrusin, A.J. Bridges, H. Zhou, H.D.H. Showalter, R.T. Winters, W.R. Leopold, D.W. Fry, J.M. Nelson, V. Slintak, W.L. Elliot, B.J. Roberts, P.W. Vincent, and S.J. Patmore Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor J. Med. Chem. 42 1999 1803 1815
22. D.W. Fry, A.J. Bridges, W.A. Denny, A. Doherty, K.D. Greis, J.L. Hicks, K.E. Hook, P.R. Keller, W.R. Leopold, J.A. Loo, D.J. McNamara, J.M. Nelson, V. Sherwood, J.B. Smaill, S. Trumpp-Kallmeyer, and E.M. Dobrusin Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor Proc. Natl. Acad. Sci. U. S. A. 95 1998 12022 12027
23. A. Wissner, D.M. Berger, D.H. Boschelli, M.B. Floyd, L.M. Greenberger, B.C. Gruber, B.D. Johnson, N. Mamuya, R. Nilakantan, M.F. Reich, R. Shen, H.-R. Tsou, E. Upeslacis, Y.F. Wang, B. Wu, F. Ye, and N. Zhang 4-Anilino-6,7- dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7- dialkoxyquinazoline inhibitors J. Med. Chem. 43 2000 3244 3256
24. J.B. Smaill, H.D.H. Showalter, H. Zhou, A.J. Bridges, D.J. McNamara, D.W. Fry, J.M. Nelson, V. Sherwood, P.W. Vincent, B.J. Roberts, W.L. Elliott, and W.A. Denny Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor J. Med. Chem. 44 2000 429 440
25. G.W. Rewcastle, W.A. Denny, A.J. Bridges, H. Zhou, D.R. Cody, A. McMichael, and D.W. Fry Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor J. Med. Chem. 38 1995 3482 3487
26. GOLD 4.1. www.ccdc.cam.ac.uk.
27. H.-R. Tsou, N. Mamuya, B.D. Johnson, M.F. Reich, B.C. Gruber, F. Ye, R. Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R. Davis, F.E. Koehn, L.M. Greenberger, Y.-F. Wang, and A. Wissner 6-Substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity J. Med. Chem. 44 2001 2719 2734
28. R. Albuschat, W. Löwe, M. Weber, P. Luger, and V. Jendrossek 4-Anilinoquinazolines with lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties Eur. J. Med. Chem. 39 2004 1001 1011
29. B. Marvania, P.-C. Lee, R. Chaniyara, H. Dong, S. Suman, R. Kakadiya, T.-C. Chou, T.-C. Lee, A. Shah, and T.-L. Su Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates Bioorg. Med. Chem. 19 2011 1987 1998
30. E. Knippel, M. Knippel, M. Michalik, H. Kelling, and H. Kristen On the geometric isomers of ethyl 2-nitro-3-ethoxyacrylate, ethyl 2-nitro-3- phenylaminoacrylate and ethyl 2-cyano-3-phenylaminoacrylate Tetrahedron 33 1977 231 234
31. W. Bottomley, J.N. Phillips, and J.G. Wilson H-N-C-H coupling in the NMR spectra of 3-aminoacrylic esters Tetrahedron Lett. 8 1967 2957 2961
32. A.E. Wakeling, A.J. Barker, D.H. Davies, D.S. Brown, L.R. Green, S.A. Cartlidge, and J.R. Woodburn Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines Breast Cancer Res. Treat. 38 1996 67 73
33. K. Wosikowski, D. Schuurhuis, K. Johnson, S.E. Bates, K.D. Paull, T.G. Myers, and J.N. Weinstein Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns J. Natl. Cancer Inst. 89 1997 1505 1515
34. R.H. Shoemaker The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 6 2006 813 823
35. X. Wu, M. Li, Y. Qu, W. Tang, Y. Zheng, J. Lian, M. Ji, and L. Xu Design and synthesis of novel gefitinib analogues with improved anti-tumor activity Bioorg. Med. Chem. 18 2010 3812 3822
36. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748
37. C.-H. Yun, T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, M. Meyerson, and M.J. Eck Structures of lung cancer-derived EGFr mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 2007 217 227
38. S. Madapa, Z. Tusi, A. Mishra, K. Srivastava, S.K. Pandey, R. Tripathi, S.K. Puri, and S. Batra Search for new pharmacophores for antimalarial activity. Part II: synthesis and antimalarial activity of new 6-ureido-4- anilinoquinazolines Bioorg. Med. Chem. 17 2009 222 234
39. S. Botros, K.M. Ghoneim, and M. Khalifa synthesis of certain nitroquinazoline-dervatives structurally related to some chemotherapeutic agents Egypt. J. Pharm. Sci. 13 1972 11 21
40. H.A.A. Shady, S.L. El-Ansary, D.A.A. El-Ella, and N.A. Farag Benzopyranone derivatives (Part 1): synthesis of various benzopyranoylimidazolidinetriones, arylpyranobenzoxazinone, pyranobenzoxazinetrione and benzopyranoyl-triazinetrione derivatives of potential CNS depresant activity Bull. Fac. Pharm. Cairo Univ. 42 2004 31 42
41. M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker, and M.R. Boyd Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay Cancer Res. 48 1988 589 601
42. M.R. Grever, S.A. Schepartz, and B.A. Chabner The National Cancer Institute: cancer drug discovery and development program Semin. Oncol. 19 1992 622 638
43. Accelry's Discovery Studio 2.5.5, Accelrys Software Inc., San Diego, 2010.
44. B.R. Brooks, R.E. Bruccoleri, B.D. Olafson, D.J. States, S. Swaminathan, and M. Karplus CHARMM: a program for macromolecular energy, minimization, and dynamics calculations J. Comp. Chem. 4 1983 187 217
45. P. Debye Näherungsformeln für die Zylinderfunktionen für große Werte des Arguments und unbeschränkt veränderliche Werte des Index Mathematische Annalen 67 1909 535 558
46. R. Fletcher, and C.M. Reeves Function minimization by conjugate gradients Comput. J. 7 1964 149 154
47. K. Choowongkomon, O. Sawatdichaikul, N. Songtawee, and J. Limtrakul Receptor-based virtual screening of EGFR kinase inhibitors from the NCI diversity database Molecules 15 2010 4041 4054